Company intelligence / Profile preview

RMDM Group

London, England, United Kingdomrmdm.group ↗

Ownership: Private
Development stage: Commercial

Overview

RMDM Group has developed the PanTum Detect test, a liquid biopsy for early multi-cancer detection, with recent whitepapers highlighting its potential to transform screening programs. The company is also developing a patented prodrug, Oxybenfothiamine, targeting TKTL1 to improve outcomes in difficult-to-treat cancers; this program is currently in early clinical trials. Their approach combines diagnostics, therapeutics, and nutraceutical solutions for comprehensive disease prevention and management.

Therapeutic areas: OncologyMetabolic Disorders
Modalities: Small molecule (prodrug Oxybenfothiamine)Diagnostic test (liquid biopsy/multi-cancer detection)Nutraceuticals ("natural sugars")
Industry: Biotech

Partnerships

none specified in public sources as of June 2025.

Beyond the preview

Go deeper on RMDM Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RMDM Group.

Explore the full profile